Modality
Cell Therapy
MOA
SOS1i
Target
PD-L1
Pathway
Notch
FL
Development Pipeline
Preclinical
~Apr 2016
→ ~Jul 2017
Phase 1
~Oct 2017
→ ~Jan 2019
Phase 2
Apr 2019
→ Nov 2025
Phase 2Current
NCT06750413
1,157 pts·FL
2019-04→2025-11·Completed
NCT03860435
1,038 pts·FL
2023-10→TBD·Not yet recruiting
2,195 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-11-065mo agoPh3 Readout· FL
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P2/3
Complet…
P2/3
Not yet…
Catalysts
Ph3 Readout
2025-11-06 · 5mo ago
FL
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06750413 | Phase 2/3 | FL | Completed | 1157 | VA |
| NCT03860435 | Phase 2/3 | FL | Not yet recr... | 1038 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 |